Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof
By Human Services Department, National Institutes of Health, Health · Oct 8, 2026, 11:00 PM CDT
The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Korea National Institute of Health, located in Cheongju-si, Chungcheongbuk-do, South Korea to practice the invention embodied in the patent application listed in the Supplem
Excerpt shown under fair-use limits. Full text remains with the original publisher.
People in this coverage
Explore their history and attributable record. Being mentioned does not imply endorsement.
Layer 1 · Claims & fact checks
AI analysisLayer 3 · Reporting analysis
AI analysisformalThe language is formal and bureaucratic, typical of government notices, using precise institutional identifiers and legal terminology.
neutralThe statement presents the intended action without evaluative language, maintaining a neutral tone.
Context
AI analysisMissing context
The notice does not provide details about the specific patent application (e.g., title, claims, filing date), the terms of the proposed license (e.g., duration, financial considerations), the intended commercial or research use, or any competing interests that might affect the decision.
Important context
The announcement originates from a U.S. federal health agency (NIAID) and concerns a potential technology transfer to a foreign public health institute (KNIH). Such licenses can affect the development and distribution of medical countermeasures for Severe Fever With Thrombocytopenia Syndrome virus.
Opinion vs. reporting
AI analysisThe text is purely factual reporting of a contemplated licensing action; it contains no opinion or editorial commentary.